GLP-1 treatment protects against EndMT through inhibiting the activation of poly (ADP-ribose) polymerase 1 (PARP-1) which can elicit Smad3 and transforming growth factor (TGF)-1 responses
Additionally, diabetes-related emotional distress and depression symptom severity have been identified as risk factors for medication non-adherence in T2DM [136, 137]
Therefore, comparison of baseline characteristics was aimed to the semaglutide 1mg arm in the SURPASS2 refined population and the full population of SUSTAIN FORTE
About the Author: Edison de Mello, MD, PhD, the author of Bloated: How to Eat Without Pain is an integrative physician, researcher, and educator specializing in functional and metabolic medicine
Questions you want answered write them down so you dont forget
Semaglutide activates only GLP-1 receptors